COVID-19
“At the end of the day, it’s not about analysis of expenses and profits, it’s about the wife that will lose her husband, it’s about the granddaughter that will lose her grandfather. It’s about you and me. It’s about stopping this carnage.” – Ryan Saadi, CEO
Healthier world through equitable access to advanced lifesaving innovations
Latest News
Businesswire – May 11th, 2021
About Us
Tevogen Bio brings together an experienced team of scientists, public health experts, physicians, and life sciences professionals with the goal of advancing global health by investigating the potential of scalable therapies and vaccines.
The company’s mission is to leverage its proprietary immunotherapy platform to develop investigational therapies in oncology, viral vaccines and harnessing its targeted T cell therapy to develop investigational products to treat viral infections such as COVID-19 and Influenza.
Clinical-Stage Biotechnology Company
New Jersey, USA
Our Proprietary T Cell Technology
Tevogen’s unique T cell therapy approach is a major scientific breakthrough under development and investigation to treat COVID-19, Influenza, almost all Solid Tumors and common Hematologic Malignancies.
Therapeutic Area
Tevogen Virology | COVID-19, Influenza
Investigational Off-The-Shelf T Cell Therapy for High Risk COVID-19 Patients
Investigational Off-The-Shelf T Cell Therapy for Hospitalized Influenza Patients
Investigational Bivalent COVID-19 & Influenza Vaccine
Tevogen Oncology | Hematology and Solid Tumors
Investigational targeted T cell therapy for Melanoma, Cervical Cancer, Hodgkin’s Lymphoma, Her2 Positive Breast Cancer, Nasopharyngeal Cancer
Current Pipeline | Virology
Current Pipeline | Oncology
Tevogen Bio is dedicated to finding curative and preventive treatments for COVID-19
Investors Relations
Message From the CEO
Tevogen was created based on the audacious goal of finding a cure for cancer. This dream inspired us to pursue the development of life-saving therapies for some of the most prevalent illnesses plaguing humanity today.
Our success is rooted in passion and perseverance, and is backed by rigorous science. However, our unrelenting optimism – and belief that learning and adapting means improving – is what propelled us to this moment.
Our corporate culture encourages people to contribute their unique and diverse perspectives, to harness their optimism and creativity, and to be ready to learn and develop solutions together towards a common and greater purpose. We all are different and think differently, it’s okay to fail and make mistakes but learn from the failures – that mindset, respect for each other and irrational optimism is what has made Tevogen a reality.
I am confident in Tevogen’s success, and in our investigational therapies and vaccines. We have brought together accomplished experts in immunotherapy and vaccine development to contribute their knowledge in a practical and efficient way. Tevogen is uniquely positioned to combat several large-scale health problems of today, including COVID-19 and Influenza. I am equally confident in the cancer solutions our oncology portfolio will contribute.
One of our objectives is to ensure that all people, regardless of socioeconomic status, are able to afford our therapies. Affordability of life-saving healthcare is a major challenge of our time. As the founder of Tevogen and its CEO, I am personally delighted to see that what started as an intrepid goal may very well play a critical role in overcoming the biggest public health crisis of our time.
Ryan Saadi, MD, MPH
CEO, Tevogen Bio
© 2021 Tevogen Bio. All Rights Reserved.